0EAP Stock Overview
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Euroapi S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.10 |
| 52 Week High | €12.16 |
| 52 Week Low | €2.28 |
| Beta | 0.56 |
| 11 Month Change | 1.44% |
| 3 Month Change | 56.79% |
| 1 Year Change | -65.76% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0EAP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.6% | -1.9% | -0.5% |
| 1Y | -65.8% | 4.9% | 7.9% |
Return vs Industry: 0EAP underperformed the UK Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: 0EAP underperformed the UK Market which returned 7.9% over the past year.
Price Volatility
| 0EAP volatility | |
|---|---|
| 0EAP Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0EAP's share price has been volatile over the past 3 months.
Volatility Over Time: 0EAP's weekly volatility has decreased from 13% to 7% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3,329 | Ludwig De Mot | www.euroapi.com/en |
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. It provides contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances, as well as lipids. The company was incorporated in 2020 and is based in Paris, France.
Euroapi S.A. Fundamentals Summary
| 0EAP fundamental statistics | |
|---|---|
| Market cap | €383.15m |
| Earnings (TTM) | -€287.30m |
| Revenue (TTM) | €971.30m |
0.4x
P/S Ratio-1.3x
P/E RatioIs 0EAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0EAP income statement (TTM) | |
|---|---|
| Revenue | €971.30m |
| Cost of Revenue | €805.80m |
| Gross Profit | €165.50m |
| Other Expenses | €452.80m |
| Earnings | -€287.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 11, 2025
| Earnings per share (EPS) | -3.02 |
| Gross Margin | 17.04% |
| Net Profit Margin | -29.58% |
| Debt/Equity Ratio | 50.9% |
How did 0EAP perform over the long term?
See historical performance and comparison